Nieuws hepatitis


balk2.jpg (42734 bytes)

Google


Nieuw wapen tegen Hepatitis C-virus van Florida State wetenschappers

Tijdens tests uitgevoerd op mensen met een veelbelovend nieuw middel dat het Hepatitis C-virus (HCV) aanpakt zonder het immuunsysteem uit te schakelen, leken sommige behandelde HCV-soorten resistent te raken tegen het middel. Daarop heeft een team biologen, chemici en biomedische onderzoekers van de Florida State University een nieuwe genetische screeningmethode ontwikkeld dat de resistent geworden HCV-varianten en de mechanismen die op moleculair niveau zorgen dat een HCV-soort resistent wordt, kan identificeren. Met deze informatie kunnen medicijnontwikkelaars specifieke behandelingen ontwikkelen waarmee een HCV-variant om de tuin wordt geleid en niet resistent wordt.

Link

Annelies


Gen tegen bijwerking

DNA-afwijking beschermt tegen bloedarmoede bij behandeling van hepatitis C

Link


Hepatitis C Virus May Need Help of Enzyme to Cause Liver Disease, Pitt Study Finds

A key enzyme may explain how hepatitis C infection causes fatty liver – a buildup of excess fat in the liver, which can lead to life-threatening diseases such as cirrhosis and liver cancer, report University of Pittsburgh Graduate School of Public Health and School of Medicine researchers. The study, published in the July 9 online issue of Hepatology, shows that an enzyme known to play a major role in lipid production, fatty acid synthase (FAS), was highly elevated in human liver cells exposed to the hepatitis C virus. While preliminary, the research suggests that testing for elevated levels of FAS could help determine which patients with hepatitis C virus may go on to develop more serious, long-lasting health consequences brought on by fatty liver.

Lees verder


May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?

While older large series of patients with hepatic granulomas have found sarcoidosis and tuberculosis to be the most common causes of hepatic granulomas, recent works have noted some patients with chronic hepatic C and hepatic granulomas and no other obvious associations. Today, patients that undergo liver biopsy often have chronic hepatitis C that is being staged prior to possible anti viral therapy. The age of HIV and immunosuppression for organ transplants has also made opportunistic infections associated with hepatic granulomas more likely. A research article to be published on November 7, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Ned Snyder from the University of Texas medical branch report a retrospective study of over 4 000 liver biopsies as well as a prospective study of 240 patients with chronic hepatitis C undergoing routine liver biopsies. They found that the most common association for hepatic granulomas was chronic hepatitis C. In the prospective study of patients with stable hepatitis C, almost 1% had hepatic granulomas.

Lees verder


Stem cells from umbilical cord used in the treatment of hepatic diseases

Researchers of the University of Granada and the University of León (Spain) have proved that human umbilical cord blood mononuclear cells can be an effective alternative to bone marrow. This work, accepted to be published by the journal Cell Transplantation, means a significant advance in regenerative hepatic medicine.

Lees verder


Who will recover spontaneously from hepatitis C virus infection

An eight-year study led by Dr. Sabine Mihm from from Georg-August-Universität has investigated 67 spontaneously recovered patients and found that co-infection by hepatitis B virus is associated with a higher possibility of self recovery. In addition, patients who self recovered usually have lower levels of HCV antibody. But on the other hand, the researchers also found that active iv drug users are less likely to self recover.

Lees verder


Treating patients with psychiatric disorders for hepatitis C

People with severe mental illnesses are far more likely to be infected with hepatitis C virus compared to the general population.

Lees verder


Grapefruit compound may help combat hepatitis C infection

A compound that naturally occurs in grapefruit and other citrus fruits may be able to block the secretion of hepatitis C virus from infected cells, a process required to maintain chronic infection. A team of researchers from the Massachusetts General Hospital Center for Engineering in Medicine report that the viral secretion required to pass on infection may be blocked by the common flavonoid naringenin.

Lees verder


New hope for hepatitis C sufferers

Adelaide scientists will lead a $2 million five-year project to develop new vaccines and explore better treatment options for hepatitis C sufferers.

Lees verder


Interferon as long-term treatment for hepatitis C not effective, report HALT-C researchers

Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study. Results of the 3½-year study, called the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial, appear in today’s issue of The New England Journal of Medicine. The researchers found no difference in the rate of progression of liver disease among patients who received interferon and those who did not.“It wasn’t that there was an insignificant difference; there was absolutely no difference whatsoever in the progression to cirrhosis and other disease complications,” said Dr. William M. Lee, professor of internal medicine at UT Southwestern and a principal investigator for the study. “It is a negative study but an important one.”

Lees verder


Hepatitis C Treatment Reduces the Virus but Liver Damage Continues

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds. These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) and are reported in the Dec. 4 issue of the New England Journal of Medicine. HALT-C was funded by the National Institutes of Health (NIH) with additional support from Hoffmann-La Roche Inc. "The results from HALT- C show without question that maintenance therapy with peginterferon does not prevent progression of liver disease among patients who have failed prior treatments," said James Everhart, M.D., project scientist for HALT-C in the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the principal sponsor of HALT-C at NIH. "These findings heighten the incentive to develop more effective drugs for patients with severe liver disease due to hepatitis C."

Lees verder


 

 


 


View My Stats